<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929849</url>
  </required_header>
  <id_info>
    <org_study_id>10420</org_study_id>
    <nct_id>NCT02929849</nct_id>
  </id_info>
  <brief_title>Satiety and Glucose Indices in Adults</brief_title>
  <official_title>Influence of Herb With Alpha-glucosidase Properties (Salacia Chinensis) on Appetite, Glucose and Hormonal Factors: A Double Blind Randomized Placebo Controlled-crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OmniActive Health Technologies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an herb with known alpha-glucosidase&#xD;
      inhibitor properties (Salacia Chinensis, SC), affects postprandial appetite ratings and&#xD;
      glucose indices in overweight/obese individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects are randomly assigned (double blinded) to 300 mg SC, 500 mg SC or placebo using a&#xD;
      cross-over design on three different days (1 month wash out). Subjects consuming a capsule&#xD;
      containing placebo or treatment(s) are examined before and after a fixed breakfast meal (50%&#xD;
      carbohydrate; 30% fat; 20% protein).&#xD;
&#xD;
      Subjective appetite sensations are rated using visual analog scales (VAS) for hunger,&#xD;
      satiety, fullness, and prospective food intake. In addition, the desire for specific tastes&#xD;
      is analyzed and measurements are taken twice before breakfast (fasting baseline). After&#xD;
      baseline screening and blood draw, postprandial appetite and taste perception ratings and&#xD;
      blood will be obtained at multiple time points during the 3 hour postprandial period (30, 60,&#xD;
      90, 120,180 min). Blood will be analyzed for glucose/insulin, gut peptides, and other markers&#xD;
      in response to the meal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Appetite ratings (VAS) at either dose compared to placebo compared to placebo)</measure>
    <time_frame>Change from Baseline and 3 hours</time_frame>
    <description>Visual analog scale (VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose indices (at either dose vs placebo)</measure>
    <time_frame>Change from Baseline and 3 hours</time_frame>
    <description>serum markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Taste perception (dose compared to placebo)</measure>
    <time_frame>Change from Baseline and 3 hours</time_frame>
    <description>visual analog scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Appetite regulating hormones and other markers at either dose or placebo</measure>
    <time_frame>Change from Baseline and 3 hours</time_frame>
    <description>blood</description>
  </other_outcome>
  <other_outcome>
    <measure>Bone Turnover markers at either dose or placebo</measure>
    <time_frame>Change from baseline over 3 hours</time_frame>
    <description>blood</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>300mg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg Salacia Chinensis (SC). This will be compared to placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500mg SC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg Salacia Chinensis (SC). This will be compared to placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The investigators will examine subjects before and during a 3 hour period after subjects consume a Placebo capsule and a fixed breakfast meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>300 mg SC</intervention_name>
    <description>Salacia (T1) capsule given with breakfast (mixed meal tolerance test)</description>
    <arm_group_label>300mg SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>500 mg SC</intervention_name>
    <description>Salacia (T2) capsule given with breakfast (mixed meal tolerance test)</description>
    <arm_group_label>500mg SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule given with breakfast (mixed meal tolerance test)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI - overweight or stage 1 obesity&#xD;
&#xD;
          -  Must be willing and able to visit the geographic vicinity of New Brunswick, NJ&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (BP) [systolic BP&gt; 140 and/or diastolic BP&gt; 90]&#xD;
&#xD;
          -  Fasting blood glucose &gt;126&#xD;
&#xD;
          -  Subject has a significant history or current presence of treated or untreated bleeding&#xD;
             disorder, diabetes mellitus, thyroid disease, tachyarrhythmia, heart disease, kidney&#xD;
             disease, or liver disease.&#xD;
&#xD;
          -  History of chronic conditions and on prescription medication, surgery and or any&#xD;
             treatment&#xD;
&#xD;
          -  Any significant GI condition that would severely interfere with the evaluation of the&#xD;
             study product including but not limited to inflammatory bowel disease (Ulcerative&#xD;
             Colitis or Crohn's), history of frequent diarrhea, history of surgery for weight loss&#xD;
             (including gastric bypass or lapband), history of perforation of the stomach or&#xD;
             intestines, gastroparesis, clinically important lactose intolerance&#xD;
&#xD;
          -  History or presence of all cancers in the prior two years.&#xD;
&#xD;
          -  Participation in a clinical study with exposure to any registered and non-registered&#xD;
             drug product within 30 days prior.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Subjects who are currently on any weight loss diets, weight loss regimen&#xD;
&#xD;
          -  Subjects currently taking prescription medication for hypertension, cardiovascular&#xD;
             disease, diabetes and/or other chronic conditions.&#xD;
&#xD;
          -  Subject currently suffers from a sleep disorder and/or has a known history of (or is&#xD;
             currently being treated for) clinical depression, eating disorder(s) or any other&#xD;
             psychiatric condition(s), which in the opinion of the investigator, might put the&#xD;
             subject at risk and/or confound the results of the study.&#xD;
&#xD;
          -  Subject has a known allergy or sensitivity to any ingredient in the test product.&#xD;
&#xD;
          -  Subject has any medical condition or uses any medication, nutritional product, dietary&#xD;
             supplement or program, which in the opinion of the investigator, might interfere with&#xD;
             the conduct of the study or place the subject at risk.&#xD;
&#xD;
          -  Subject has a history of difficulty swallowing large pills or tablets.&#xD;
&#xD;
          -  Investigator is uncertain about subject's capability or willingness to comply with the&#xD;
             protocol requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sue Shapses, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rutgers University</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kissileff HR, Thornton JC, Torres MI, Pavlovich K, Mayer LS, Kalari V, Leibel RL, Rosenbaum M. Leptin reverses declines in satiation in weight-reduced obese humans. Am J Clin Nutr. 2012 Feb;95(2):309-17. doi: 10.3945/ajcn.111.012385. Epub 2012 Jan 11.</citation>
    <PMID>22237063</PMID>
  </reference>
  <reference>
    <citation>Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48.</citation>
    <PMID>10702749</PMID>
  </reference>
  <reference>
    <citation>Ibrügger S, Kristensen M, Mikkelsen MS, Astrup A. Flaxseed dietary fiber supplements for suppression of appetite and food intake. Appetite. 2012 Apr;58(2):490-5. doi: 10.1016/j.appet.2011.12.024. Epub 2012 Jan 5.</citation>
    <PMID>22245724</PMID>
  </reference>
  <reference>
    <citation>Hao L, Schlussel Y, Fieselmann K, Schneider SH, Shapses SA. Appetite and Gut Hormones Response to a Putative α-Glucosidase Inhibitor, Salacia Chinensis, in Overweight/Obese Adults: A Double Blind Randomized Controlled Trial. Nutrients. 2017 Aug 12;9(8). pii: E869. doi: 10.3390/nu9080869.</citation>
    <PMID>28805670</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>October 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers University</investigator_affiliation>
    <investigator_full_name>Sue Shapses</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>rules/regulations would need to be confirmed</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

